{"id":"NCT00836693","sponsor":"Eli Lilly and Company","briefTitle":"Effect of Tadalafil Once a Day in Men With Erectile Dysfunction","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2009-02-04","resultsPosted":"2011-01-04","lastUpdate":"2011-01-04"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Erectile Dysfunction"],"interventions":[{"type":"DRUG","name":"tadalafil","otherNames":["Cialis","LY450190"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Tadalafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are naïve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability.","primaryOutcome":{"measure":"Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Tadalafil","deltaMin":15.5,"sd":6},{"arm":"Placebo","deltaMin":16,"sd":6.27}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":21,"countries":["Germany","Greece","Italy","Poland","Spain"]},"refs":{"pmids":["24119319","22790642","21707928"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":147},"commonTop":["Nasopharyngitis","Back pain","Dyspepsia","Myalgia","Headache"]}}